NCT05538026View on ClinicalTrials.gov

Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis

NACompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

January 1, 2022

Study Completion Date

January 10, 2022

Conditions
Ulcerative Colitis Chronic MildInflammatory Bowel Diseases
Interventions
DRUG

Mesalazine

daily dose of 3 g (2 g orally + 1 g rectally)

BIOLOGICAL

Fecal transplantation

Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.

Trial Locations (2)

01601

Bogomolets National Medical University, Kyiv

Unknown

Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv

All Listed Sponsors
collaborator

Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine

UNKNOWN

lead

Bogomolets National Medical University

OTHER

NCT05538026 - Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis | Biotech Hunter | Biotech Hunter